A library of N-9- and N-7-substituted 1,2,3 triazole analogues were generated on the 2,6-di-substituted purine upon reaction with various substituted aromatic azides. The synthesised analogues were screened for in vitro cytotoxic activity against various human cancer cell lines like (HCT-1 (colon), THP-1 (leukaemia), IMR-32 (neuroblastoma) and A-549 (lung)). From the bioassay results, it was observed that even though most of the synthesized derivatives exhibited a good potency against various screened cancer cell lines, but few of the analogues like 9a, 9b and 9e were found to be the most potent analogues in the series, with compound 9a showing IC50 values of 0.08 and 0.4 μM against THP-1 and A-549 cell lines, respectively.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Methylene group attached to benzene ring of benzyl amine
Methylene group attached to Triazole ring
De Clercq E (1997) Current and potential therapies for the treatment of herpes-virus infections. Clin Microbiol Rev 10:674–669
Hansen SW, Skovsgaard T, Sorensen JB (1985) Treatment of small cell lung cancer with 6-mercaptopurine: A phase II study. Cancer Treat Rep 69:555
Havlicek L, Hanus J, Vesely J, LeClerc S, Meijer L, Shaw G, Strnad M (1997) 8-Azapurines as new inhibitors of cyclin-dependent kinases. J Med Chem 40:408–412
Jeannette CA, Christian EP, Álvaro CM, Ricardo AT, Mario F, Maria JT, Adam A, Margot P, Cristian OS (2015) Synthesis and pharmacophore modelling of 2,6,9-trisubstituted purine derivatives and their potential role as apoptosis-inducing agents in cancer cell lines. Molecules 20(4):6808–6826
Kay NE (1981) Abnormal T cell subpopulation function in CLL: excessive suppressor and deficient helper activity with respect to B cell proliferation. Blood 57:418–420
Legraverend M, Grierson DS (2006) The purines: potent and versatile small molecule inhibitors and modulators of key biological targets. Med Chem 14:3987–4006
MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65:5399–5407
Marr JJ (1991) Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J Lab Clin Med 118:111–119
Mary EL, Patrick EC, Satya N, Brian KL (2015) Cyclin-dependent kinase inhibitors as anticancer therapeutics. Mol Pharmacol 88:846–852
Masson C (1983) Treatment of herpes with acyclovir. Presse Med 12:1399–1400
McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP (2002) Int J Cancer 102:463–468
Melroy J, Nair V (2005) The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS. Curr Pharm Des 11:3847–3852
Munshi PN, Lubin M, Bertino JR (2014) 6-Thioguanine: a drug with unrealized potential for cancer therapy. Oncologist 19:760–765
Nabhan C, Gartenhaus RB, Tallman MS (2004) Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukaemia: dawn of a new era. Leuk Res 28(5):429–442
Panos F, Bruce CA, Michael LG (1996) Purine analogs for the treatment of low-grade lymph proliferative disorder. Oncologist 1(3):125–139
Perez OD, Chang YT, Rosania G, Sutherlin D, Schultz PG (2002) Inhibition and reversal of myogenic differentiation by purine-based microtubule assembly inhibitors. Chem Biol 9(4):475–483
Quan DJ, Peters MG (2004) Antiviral therapy: nucleotide and nucleoside analogs. Clin Liver Dis 8(2):371–385
Rosemeyer H (2004) The chemo diversity of purine as a constituent of natural products. Chem Biodivers 1:361–401
Saman MV, Salim KY, Danter WR, Koropatnick J (2018) PLoS ONE 13(1):e0191766
Siegel-Lakhai WS, Rodenstein DO, Beijnen JH, Gianella-Borradori A, Schellens JHM, Talbot DC (2005) Clinical trial designs. J Clin Oncol 23:2060–2060
Vince R (1991) Synthesis and anti-HIV activity of carbovir and related carbocyclic nucleosides. Nucl Acids Symp Ser 25:193–194
Wang X, Wang L, Wu N, Ma X, Xu J (2015) Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex keratitis: corrigendum. Chin Med J 128:46–50
WS Hsieh, R Soo, BK Peh, T Loh, D Dong, D Soh, LS Wong, S Green,J Chiao, CY Cui, YF Lai, SC Lee, B Mow, R Soong, M Salto-Tellez, BC Goh (2009) Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 15:1435–1442
Welsch ME, Snyder SA, Stockwell BR (2010) Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol 2010(14):347–361
Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD, Workman P (2007) The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 6:3114–3131
We thank University of Pretoria for providing postdoctoral fellowship to JK.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Khazir, J., Mir, B.A., Chashoo, G. et al. Synthesis and anticancer activity of N-9- and N-7- substituted 1,2,3 triazole analogues of 2,6-di-substituted purine. Med Chem Res 29, 33–45 (2020). https://doi.org/10.1007/s00044-019-02456-9
- 2,6 Dichloropurine
- 1,2,3 triazoles